Accomplished scientist with a proven track record of developing and leading cancer research programs for 16 years in academia and 4 years in pharma. Demonstrated innovation by patent, new target discovery translated into clinical trial, securing +$3M in research grants (incl. NIH), and 39 peer-reviewed publications in high-impact journals. Track record of advanced managerial skills as a PI in academia and pharma for 20 years. Experience in consulting for both academia and pharma.Expert in studies of tumor cell heterogeneity, stem cells, cancer stem cells and mechanisms of drug resistance for brain tumors and epithelial cancers. Extensive experience developing in vivo cancer models including genetically engineered mouse models, xenograft models, patient-derived xenograft models and orthotopic transplant models for target identification, proof of concept and pre-clinical efficacy studies. In-depth knowledge optimizing defined culture conditions for establishing primary cultures of patient-derived tumor cultures. Used to characterize components of the tumor microenvironment, including tumor cells, CAFs, immune cells, ECM, mechanoforces, and vasculature.
Listed skills include Neuroscience, Stem Cells, Brain Tumors, Cell Culture, and 25 others.